CHICAGO — Rivaroxaban thromboprophylaxis greatly reduced venous thromboembolism among ambulatory patients with pancreatic cancer, according to results of a prespecified subgroup analysis of the CASSINI study presented at ASCO Annual Meeting.
Researchers observed no increase in major bleeding during the intervention period.
“Pancreatic cancer is a known very high-risk malignancy associated with venous thromboembolism and, in fact, by itself, has been the subject of two prior randomized trials,” Alok A. Khorana, MD, professor of medicine at Cleveland Clinic Lerner College of

Source link